Research Reports
Intas Pharmaceuticals Unlisted Shares
Intas Pharmaceuticals Share Price
DMAT
PUBLIC LIMITED
Price Chart
1W
1M
1Y
MAX
High
₹5,800
Low
₹5,800
Return
-
Intas Pharmaceuticals Essentials
As of April 30, 2026, Intas Pharmaceuticals, Unlisted Shares are trading at ₹5,800.00 per share and face value is ₹10.00/share, with a 52-week high of ₹5,800.00 and 52-week low of ₹5,800.00. The minimun lot size is None shares, and the shares are traded on .
ISIN
INE316F01011
An International Securities Identification Number (ISIN) is a code that uniquely identifies a specific securities issue. The numbers are allocated by a country's respective national numbering agency (NNA).
Face Value
10
Value of a security, as stated by its issuer. It has no relation with market price of the stock.
Total Shares
11,47,67,049
Total shares or total number of shares outstanding represents the amount of stock on the open market, including shares held by institutional investors and restricted shares held by insiders and company officers.
Market Cap
66,564.89 Cr
Market capitalization is the aggregate valuation of the company based on its current share price and the total number of outstanding shares.
Profit After Tax
2,422.77 Cr
It is the final profit left over after subtracting all operating and non operating items from net revenue.
Total Revenue
19,882.83 Cr
Gross income refers to the total income earned by an individual on a pay check before taxes and other deductions. It comprises all incomes received by an individual from all sources – including wages, rental income, interest income, and dividends.
P/E
27.48
It is a valuation parameter that measures the company's current share price relative to its per-share earnings. Generally, high P/E is Overvalued & low P/E is Undervalued.
P/B
4.17
It shows the relationship between the current price and the book value of each share. A lower P/B ratio can mean that the stock is undervalued.
Sector
Health Care
A sector is an area in which businesses share the same or a related product or service. It can also be known as an industry or market that shares common operating characteristics
Sub-sector
Pharmaceuticals
Subsectors are the divisions of a sector. They are areas that vary from the rest of the sector substantially enough to justify creating a plan just for the subsector.
Category
Mid Cap
Category is defined as a class or division of things regarded as having particular shared characteristics.
Cashflow - Operations
3,284.12 Cr
It indicates the amount of money a company brings in from its ongoing and regular operations over a fixed period of time.
About Intas Pharmaceuticals
Company Overview:
- Intas Pharmaceuticals Limited is a pharmaceutical company based in India with a global presence. Specializing in the production of generic therapeutic drugs, the company is also involved in contract clinical research and manufacturing. Operating as a vertically integrated enterprise, Intas is engaged in the complete process of pharmaceutical formulation development, manufacturing, and marketing. The company is dedicated to addressing unmet medical and societal needs on a global scale through its comprehensive pharmaceutical value chain.
- Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide with robust sales, marketing, and distribution infrastructure in markets like North America, Europe, Central & Latin America, Asia-Pacific as well as CIS and MENA countries.
- In 2006, an independent biotechnology division of Intas Pharmaceuticals was incorporated as Intas Biopharmaceuticals by Urmish Chudgar, a hematologist. Later in 2012-13, the subsidiary was merged with the parent company Intas Pharmaceuticals Limited. This division is involved in the development and manufacturing of biosimilar products based on recombinant DNA and monoclonal antibodies.
- Every Intas product and service is a testament to its uncompromising quality standards. All products are manufactured in facilities that are approved by major global regulatory agencies including the USFDA, MHRA, EMA, TGA, MCC, ANVISA, and more.
- The company faced an EU-GMP (Good Manufacturing Practice) audit in December 2006, to seek approval for a clinical trial of its biosimilar Filgrastim in Europe and was certified as EU-GMP compliant in April 2007, becoming the first company in India to receive such certification. In 2015, the company launched its first biosimilar product, Filgrastim in Europe, to treat patients with advanced HIV infection and immune system disorders such as neutropenia.
- The company was incorporated on 31 May 1985, with its registered office at Corporate House, Near Sola Bridge, S. G. Highway, Thaltej Ahmedabad Ahmedabad GJ 380054 IN.
Want to See a Detailed Investment Analysis?
Explore in-depth financial analysis, performance metrics, and key disclosures.
Intas Pharmaceuticals Media
News
Articles
Videos
Intas & Accord Expand Global Pegfilgrastim Reach with UDENYCA Acquisition
07 Aug 2025
• Express pharma
Intas Pharmaceuticals Launches Hetronifly™, India’s First Novel Immunotherapy for Small Cell Lung Cancer
04 Aug 2025
• PR Newswire
Biosimilar brand buy to help Intas Pharma take on biggies
05 Feb 2025
• Economic Times
Intas Pharmaceuticals
₹ 5,800
